

*Lilly***Fax**Eli Lilly and Company  
Lilly Corporate Center  
Indianapolis, Indiana 46285  
U.S.A.

Legal Department - Patent Division

**To: Examiner F. T. Moezie**Company: USPTO  
Fax: 9-1-703-746-5101  
Phone:  
Date: August 8, 2001From: Mark J. Stewart, Ph.D.  
Fax: 317-276-5172  
Phone: 317-276-0280  
Total Pages: 8

Applicants	:	Hermeling, Ronald N., <i>et al.</i>	)
Serial No.	:	09/209,799	)
Filed	:	December 11, 1998	)
For	:	Glucagon-Like Peptide-1 Crystals	)
Docket No.	:	X-10242	)

)Group Art Unit:  
1653  
)  
) Examiner:  
) F. Moezie  
)

*Official - Enter  
F. M. 8/8/01***Privileged and Confidential Communication**

If there are any transmittal problems please call: (317) 277-8827.

This facsimile message is intended only for the individual to whom it is addressed and may contain information that is privileged, confidential or exempt from disclosure under applicable law. If you have received this facsimile in error, please notify us immediately by telephone (collect), and return the original message to us at the above address via U.S. Postal Service.

Answers That Matter.

*G*

CERTIFICATION OF FACSIMILE TRANSMISSION	
I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.	
Cynthia Craft	
Type or print name of person signing certification	
<i>Cynthia Craft</i>	August 8, 2001
Signature	Date

**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants	: Hermeling, Ronald N., et al.	)	
Serial No.	: 09/209,799	)	
Filed	: December 11, 1998	)	Group Art Unit:
		)	1653
For	: Glucagon-Like Peptide-1	)	Examiner:
	Crystals	)	F. Moezie
Docket No.	: X-10242	)	

**AMENDMENT AFTER FINAL REJECTION**  
**UNDER 37 C.F.R. 1.116**

Assistant Commissioner for Patents  
Washington, D. C. 20231  
Sir:

OFFICIAL - ENTER  
F.M. 8/8/01

Per a phone conversation with the Examiner and Applicant's attorney on Monday, August 6, 2001, Applicants respectfully request that the Examiner enter the following amendments which the Examiner has indicated place the application in condition for allowance.

Claims 33 through 40, 42, and 75 through 76 are currently pending in the present application. The amendment presented below cancels claim 36, amends currently pending claims 33-35, 37-40, and 75, and adds new claims 77 through 79. Zinc and ammonium sulfate are now presented in separate claims. Ammonium sulfate is specified in new claims 77 through 79.

Please amend the Application as follows:

Cancel claim 36. Add new Claims 77 through 79.

G